Red blood cell (RBC) alloimmunization can be a life-threatening complication for patients with sickle cell disease (SCD) receiving therapeutic transfusions. Despite provision of extended antigen-matched donor RBCs, patients continue to develop antibodies due to high degree of polymorphisms in the immunogenic antigens in individuals of African ancestry. Identification of biomarkers of alloimmunization in this patient population is therefore of great interest and will help to identify in advance patients most likelyto make antibodies in response to transfusion Genetic as well as acquired patient-related factors are likely to influence the process of alloimmunization. We recently reported altered regulatory T cell (Treg) and T helper (Th) responses with higher circulating Th1 (IFN-?) cytokines, but lower IL-10 levels in chronically transfused SCD antibody producers as compared to SCD non-producers. Our preliminary data indicate that in alloimmunized SCD patients, monocyte subsets, which are increasingly recognized as modulators of T cell responses, differentially suppress regulatory T cell (Treg) proliferation while promoting effector T cell expansion in part by altered responsiveness to IL-12 and IL-10. We have further identified lower levels of heme oxygenase I (HO-1), known for its anti-inflammatory and immunosuppressive role, in monocytes from alloimmunized SCD patients and altered Treg/Th development in response to hemin, a surrogate marker for transfused RBC breakdown products. We hypothesize that inadequate levels/activity of HO-1 alters the anti- inflammatory state of the sickle innate immune cells following RBC transfusion, resulting in pathogenic T cell responses against RBCs and alloimmunization. We will test our hypothesis with the following specific aims: 1) to dissect the mechanism of altered monocyte control of T cell responses in alloimmunized patients with SCD, 2) to identify the mechanisms of hemin-mediated monocyte polarization in alloimmunized patients with SCD, and 3) to characterize the association between alloimmunization, low HO-1 levels and altered monocyte control of Th/Treg proliferation in a longitudinal study of SCD patients receiving monthly erythrocytopheresis. We believe that the proposed studies the ways in which innate immune abnormalities can will not only provide us with a detailed mechanistic understanding of contribute to pathogenic T cell responses in alloimmunized SCD patients, which will help future identification of biomarkers of alloimmunization with the goal that this information will ultimately help guide therapy in these patients.

Public Health Relevance

For patients with sickle cell disease (SCD), blood transfusions remain a cornerstone of treatment, with 60-90% of patients receiving RBC transfusions in their lifetime. However, some patients develop a strong immune response that rejects the transfused cells, resulting in a life- threatening complication. We believe that these individuals have certai hyperactive immune cells. Our goal is to identify these cells and understand what makes them hyperactive. This knowledge will help us to pre-screen for SCD patients who are likely to reject transfusions. It will also create a strong foundation for development of treatments to cure their hyperactive immune system.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL121415-02
Application #
8892238
Study Section
Special Emphasis Panel (ZRG1-VH-F (55))
Program Officer
Zou, Shimian
Project Start
2014-08-01
Project End
2018-04-30
Budget Start
2015-05-01
Budget End
2016-04-30
Support Year
2
Fiscal Year
2015
Total Cost
$606,459
Indirect Cost
$192,085
Name
New York Blood Center
Department
Type
DUNS #
073271827
City
New York
State
NY
Country
United States
Zip Code
10065
Zhong, Hui; Yazdanbakhsh, Karina (2018) Hemolysis and immune regulation. Curr Opin Hematol 25:177-182
Pirenne, France; Yazdanbakhsh, Karina (2018) How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions. Blood 131:2773-2781
Liu, Yunfeng; Jing, Fangmiao; Yi, Woelsung et al. (2018) HO-1hi patrolling monocytes protect against vaso-occlusion in sickle cell disease. Blood 131:1600-1610
Yazdanbakhsh, Karina; Shaz, Beth H; Hillyer, Christopher D (2017) Immune Regulation of sickle Cell Alloimmunization. ISBT Sci Ser 12:248-253
Godefroy, Emmanuelle; Liu, Yunfeng; Shi, Patricia et al. (2016) Altered heme-mediated modulation of dendritic cell function in sickle cell alloimmunization. Haematologica 101:1028-38
Yazdanbakhsh, Karina (2016) Immunoregulatory networks in sickle cell alloimmunization. Hematology Am Soc Hematol Educ Program 2016:457-461
Godefroy, Emmanuelle; Zhong, Hui; Pham, Petra et al. (2015) TIGIT-positive circulating follicular helper T cells display robust B-cell help functions: potential role in sickle cell alloimmunization. Haematologica 100:1415-25
Yazdanbakhsh, K (2015) Mechanisms of sickle cell alloimmunization. Transfus Clin Biol 22:178-81